Diagnostic Imaging Testing

PROCEDURE9 trials

Sponsors

Children's Oncology Group, National Cancer Institute (NCI), NRG Oncology, University of Washington

Conditions

Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic AdenocarcinomaAdvanced Primary Peritoneal CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Fallopian Tube High Grade Serous Adenocarcinoma

Phase 1

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Active, not recruitingNCT03939897

National Cancer Institute (NCI)Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma +2

Start: 2020-06-17End: 2026-08-14Updated: 2025-09-24

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Active, not recruitingNCT04616534

National Cancer Institute (NCI)Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma +19

Start: 2021-06-01End: 2026-05-20Updated: 2025-05-22

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

RecruitingNCT05372640

National Cancer Institute (NCI)Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma +5

Start: 2023-08-10End: 2026-06-01Target: 45Updated: 2026-04-03

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

RecruitingNCT05687110

National Cancer Institute (NCI)Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Start: 2023-07-06End: 2026-09-01Target: 43Updated: 2026-04-03

Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

RecruitingNCT02981628

Children's Oncology GroupRecurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia +1

Start: 2017-06-19End: 2026-12-31Target: 80Updated: 2026-02-23

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

RecruitingNCT05327010

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

Start: 2022-11-14End: 2027-12-31Target: 88Updated: 2026-04-03

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

RecruitingNCT06179303

University of WashingtonAnatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma +3

Start: 2024-07-22End: 2028-06-01Target: 60Updated: 2026-02-27

Phase 3

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

RecruitingNCT05646316

NRG OncologyStage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Start: 2022-12-07End: 2026-10-31Target: 428Updated: 2026-03-27

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

RecruitingNCT06422806

National Cancer Institute (NCI)Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 +3

Start: 2024-09-11End: 2026-06-30Target: 365Updated: 2026-03-31

Related Papers

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood2024-11-053 citations

PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Blood2024-11-05

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.

2022-12-0112 citations

CD22 low/Bcl-2 high Expression Identifies Poor Response to Inotuzumab in Relapsed/ Refractory Acute Lymphoblastic Leukemia

Blood2021-11-054 citations

Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).

Journal of Clinical Oncology2020-05-2011 citations

Immunotherapies for Pediatric B-Cell Acute Lymphoblastic Leukemia Patients

Oncology Times2019-04-25